Crown Coronation
Infectious Diseases
Vaccine Preventable Diseases
An international, Bayesian platform adaptive, randomized, placebo‐controlled trial assessing the effectiveness of candidate interventions in preventing COVID‐19 disease in adults.
Primary Objectives
- To determine the effectiveness of MR (or MMR) vaccine in preventing symptomatic (i.e. any of the following: cough, shortness of breath or difficulty breathing, fever, chills, muscle pain, sore throat, new loss of taste or smell, nausea, vomiting, or diarrhoea), laboratory test‐confirmed COVID‐19 in adults with repeated exposures to SARS‐CoV‐2 by day 60 after receiving the trial intervention.
- To determine the effectiveness of MR (or MMR) vaccine in mitigating the severity of COVID-19 in adults who become infected with SARS-CoV-2 by day 60 after receiving the trial intervention. Severity will be graded on a simplified version of the ordinal WHO COVID-19 severity scale.
Investigators
- Prof Sínead Delany‐Moretlwe
- Dr Darshnika Lakhoo,
- Dr Kim Comline
Other Partners & Collaborators
- COVID‐19 Therapeutics Accelerator
- Desmond Tutu HIV Foundation
- University of Cape Town
- University College London Comprehensive Clinician Trials Unit
Sponsors/Donors
- Washington University School of Medicine in St Louis, United States of America
- Wits Reproductive Health & HIV Institute, a Division of WITS HEALTH CONSORTIUM (PTY) LTD
For more about CROWN CORONATION please email rhicomms@wrhi.ac.za
